Oligomerix is seeking solutions to major unmet medical needs with over 10 years research experience in helping define the role of tau protein in neurodegenerative diseases and discovering and developing novel therapeutics for Alzheimer’s and related tauopathies.
Role of tau protein in Alzheimer’s disease:
This video shows how the loss of tau protein function leads to structural changes causing the loss of communication between neurons, a defining characteristic of Alzheimer’s disease.Oligomerix has further found that tau acquires toxic functions degrading proteins and disrupting memory formation when it forms small soluble aggregates of tau, tau oligomers.
We are discovering therapeutics that target tau protein loss of function and gain of toxicity
January 7, 2018
Oligomerix to attend JP Morgan Healthcare Conference in San Francisco, CA to conduct partnering discussions January 7 – 10, 2018
October 8, 2017
Oligomerix, Inc. Awarded National Institute on Aging SBIR Grant for Development of Alzheimer’s Disease Specific Biomarker
October 8, 2017
Oligomerix to present poster and conduct partnering discussions at Society for Neuroscience in Washington DC – November 12-15, 2017
June 6, 2017
Oligomerix to present poster and conduct partnering discussions at AAIC, London, U.K., July 16 – 20
February 10, 2017
Oligomerix to attend AD/PD 2017 and conduct partnering discussions, Vienna, Austria, March 29 – April 2
January 9, 2017
Oligomerix to attend JP Morgan Healthcare Conference in San Francisco to conduct partnering discussions, CA January 9 – 12, 2017
November 29, 2016
Oligomerix issued US Patent 9,506,051 for tau protease methods & composition using tau self-truncated fragments for drug/antibody discovery
November 15, 2016
Oligomerix to present poster at SfN 2016 in San Diego, CA
October 11, 2016
Oligomerix issued patent for methods and composition of tau oligomer US Patent 9,464,122 for drug and antibody discovery using tau trimer.
July 24, 2016
Oligomerix to present tau poster at AAIC…